Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

More than $1 billion needed annually to secure Africa's protected areas with lions.

Lindsey PA, Miller JRB, Petracca LS, Coad L, Dickman AJ, Fitzgerald KH, Flyman MV, Funston PJ, Henschel P, Kasiki S, Knights K, Loveridge AJ, Macdonald DW, Mandisodza-Chikerema RL, Nazerali S, Plumptre AJ, Stevens R, Van Zyl HW, Hunter LTB.

Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):E10788-E10796. doi: 10.1073/pnas.1805048115. Epub 2018 Oct 22.

2.

The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance.

Miners JO, Yang X, Knights KM, Zhang L.

Clin Pharmacol Ther. 2017 Sep;102(3):436-449. doi: 10.1002/cpt.757. Epub 2017 Jul 26.

PMID:
28599065
3.

Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.

Miners JO, Chau N, Rowland A, Burns K, McKinnon RA, Mackenzie PI, Tucker GT, Knights KM, Kichenadasse G.

Biochem Pharmacol. 2017 Apr 1;129:85-95. doi: 10.1016/j.bcp.2017.01.002. Epub 2017 Jan 6.

PMID:
28065859
4.

In Vitro Drug Metabolism Using Liver Microsomes.

Knights KM, Stresser DM, Miners JO, Crespi CL.

Curr Protoc Pharmacol. 2016 Sep 16;74:7.8.1-7.8.24. doi: 10.1002/cpph.9.

PMID:
27636111
5.

Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearance.

Knights KM, Spencer SM, Fallon JK, Chau N, Smith PC, Miners JO.

Br J Clin Pharmacol. 2016 Jun;81(6):1153-64. doi: 10.1111/bcp.12889. Epub 2016 Mar 14.

6.

Phosphorescence quenching of fac-tris(2-phenylpyridyl)iridium(iii) complexes in thin films on dielectric surfaces.

Ribierre JC, Ruseckas A, Staton SV, Knights K, Cumpstey N, Burn PL, Samuel ID.

Phys Chem Chem Phys. 2016 Feb 7;18(5):3575-80. doi: 10.1039/c5cp06584d. Epub 2016 Jan 11.

PMID:
26750542
7.

Measuring impact of protected area management interventions: current and future use of the Global Database of Protected Area Management Effectiveness.

Coad L, Leverington F, Knights K, Geldmann J, Eassom A, Kapos V, Kingston N, de Lima M, Zamora C, Cuardros I, Nolte C, Burgess ND, Hockings M.

Philos Trans R Soc Lond B Biol Sci. 2015 Nov 5;370(1681). pii: 20140281. doi: 10.1098/rstb.2014.0281. Review.

8.

The Nonspecific Binding of Tyrosine Kinase Inhibitors to Human Liver Microsomes.

Burns K, Nair PC, Rowland A, Mackenzie PI, Knights KM, Miners JO.

Drug Metab Dispos. 2015 Dec;43(12):1934-7. doi: 10.1124/dmd.115.065292. Epub 2015 Oct 6.

PMID:
26443648
9.

Characterization of the comparative drug binding to intra- (liver fatty acid binding protein) and extra- (human serum albumin) cellular proteins.

Rowland A, Hallifax D, Nussio MR, Shapter JG, Mackenzie PI, Brian Houston J, Knights KM, Miners JO.

Xenobiotica. 2015;45(10):847-57. doi: 10.3109/00498254.2015.1021403. Epub 2015 Mar 24.

PMID:
25801059
10.
11.

Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT).

Knights KM, Rowland A, Miners JO.

Br J Clin Pharmacol. 2013 Oct;76(4):587-602. doi: 10.1111/bcp.12086. Review.

12.

Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance.

Wattanachai N, Tassaneeyakul W, Rowland A, Elliot DJ, Bowalgaha K, Knights KM, Miners JO.

Drug Metab Dispos. 2012 May;40(5):982-9. doi: 10.1124/dmd.111.044057. Epub 2012 Feb 13.

PMID:
22331994
13.

Cardiovascular toxicity of nonsteroidal anti-inflammatory drugs: moving beyond cyclooxygenase selectivity.

Mangoni AA, Crilly MA, Knights KM.

Expert Rev Clin Pharmacol. 2011 May;4(3):299-302. doi: 10.1586/ecp.11.12. No abstract available.

PMID:
22114775
14.

Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity.

Knights KM, Mangoni AA, Miners JO.

Expert Rev Clin Pharmacol. 2010 Nov;3(6):769-76. doi: 10.1586/ecp.10.120.

PMID:
22111779
15.

[Non-steroidal anti-inflammatory drugs and risk of stroke in older patients: current controversies and research directions].

Mangoni AA, Knights KM.

G Ital Cardiol (Rome). 2011 May;12(5):341-9. doi: 10.1714/643.7499. Review. Italian.

PMID:
21593953
16.

Differential disposition of intra-renal generated and preformed glucuronides: studies with 4-methylumbelliferone and 4-methylumbelliferyl glucuronide in the filtering and nonfiltering isolated perfused rat kidney.

Wang J, Evans AM, Knights KM, Miners JO.

J Pharm Pharmacol. 2011 Apr;63(4):507-14. doi: 10.1111/j.2042-7158.2010.01244.x. Epub 2011 Mar 1.

PMID:
21401602
17.

Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation.

Miners JO, Bowalgaha K, Elliot DJ, Baranczewski P, Knights KM.

Drug Metab Dispos. 2011 Apr;39(4):644-52. doi: 10.1124/dmd.110.037036. Epub 2011 Jan 18.

PMID:
21245288
18.

Non-steroidal anti-inflammatory drugs and atherothrombotic risk in older patients: where do we stand?

Mangoni AA, Reid DM, Knights KM.

Age Ageing. 2010 Sep;39(5):530-3. doi: 10.1093/ageing/afq099. Epub 2010 Jul 27.

PMID:
20667839
19.

Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community.

Mangoni AA, Woodman RJ, Gaganis P, Gilbert AL, Knights KM.

Br J Clin Pharmacol. 2010 Jun;69(6):689-700. doi: 10.1111/j.1365-2125.2010.03627.x.

20.

Use of non-steroidal anti-inflammatory drugs and risk of ischemic and hemorrhagic stroke in the Australian veteran community.

Mangoni AA, Woodman RJ, Gilbert AL, Knights KM.

Pharmacoepidemiol Drug Saf. 2010 May;19(5):490-8. doi: 10.1002/pds.1945.

PMID:
20437458
21.

Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18beta-glucuronidation: a potential drug interaction.

Knights KM, Bowalgaha K, Miners JO.

Drug Metab Dispos. 2010 Jul;38(7):1011-4. doi: 10.1124/dmd.110.032870. Epub 2010 Mar 19.

PMID:
20304966
23.

Renal UDP-glucuronosyltransferases and the glucuronidation of xenobiotics and endogenous mediators.

Knights KM, Miners JO.

Drug Metab Rev. 2010 Feb;42(1):63-73. doi: 10.3109/03602530903208561.

PMID:
19780654
24.

Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs.

Knights KM, Winner LK, Elliot DJ, Bowalgaha K, Miners JO.

Br J Clin Pharmacol. 2009 Sep;68(3):402-12. doi: 10.1111/j.1365-2125.2009.03469.x.

25.
26.

Characterization of the binding of drugs to human intestinal fatty acid binding protein (IFABP): potential role of IFABP as an alternative to albumin for in vitro-in vivo extrapolation of drug kinetic parameters.

Rowland A, Knights KM, Mackenzie PI, Miners JO.

Drug Metab Dispos. 2009 Jul;37(7):1395-403. doi: 10.1124/dmd.109.027656. Epub 2009 Apr 27.

PMID:
19398502
27.

Advocacy for mothers with psychiatric illness: a clinical perspective.

Lagan M, Knights K, Barton J, Boyce PM.

Int J Ment Health Nurs. 2009 Feb;18(1):53-61. doi: 10.1111/j.1447-0349.2008.00576.x. Review.

PMID:
19125787
28.

Kinetic analysis of growth rate, ATP, and pigmentation suggests an energy-spilling function for the pigment prodigiosin of Serratia marcescens.

Haddix PL, Jones S, Patel P, Burnham S, Knights K, Powell JN, LaForm A.

J Bacteriol. 2008 Nov;190(22):7453-63. doi: 10.1128/JB.00909-08. Epub 2008 Sep 19.

29.

In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway.

Kerdpin O, Knights KM, Elliot DJ, Miners JO.

Biochem Pharmacol. 2008 Jul 15;76(2):249-57. doi: 10.1016/j.bcp.2008.04.014. Epub 2008 May 1.

PMID:
18541222
30.
31.

The "albumin effect" and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9.

Rowland A, Elliot DJ, Knights KM, Mackenzie PI, Miners JO.

Drug Metab Dispos. 2008 May;36(5):870-7. doi: 10.1124/dmd.107.019885. Epub 2008 Feb 6.

PMID:
18256202
32.

Triplet exciton diffusion and phosphorescence quenching in iridium(III)-centered dendrimers.

Ribierre JC, Ruseckas A, Knights K, Staton SV, Cumpstey N, Burn PL, Samuel ID.

Phys Rev Lett. 2008 Jan 11;100(1):017402. Epub 2008 Jan 10.

PMID:
18232820
33.
34.

Amino acid conjugation: contribution to the metabolism and toxicity of xenobiotic carboxylic acids.

Knights KM, Sykes MJ, Miners JO.

Expert Opin Drug Metab Toxicol. 2007 Apr;3(2):159-68. Review.

PMID:
17428148
35.

Glucuronidation of fenamates: kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7.

Gaganis P, Miners JO, Knights KM.

Biochem Pharmacol. 2007 May 15;73(10):1683-91. Epub 2007 Jan 28.

PMID:
17343829
36.

Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation.

Rowland A, Gaganis P, Elliot DJ, Mackenzie PI, Knights KM, Miners JO.

J Pharmacol Exp Ther. 2007 Apr;321(1):137-47. Epub 2007 Jan 19.

PMID:
17237258
37.
38.

Novel mechanisms of nonsteroidal anti-inflammatory drug-induced renal toxicity.

Knights KM, Tsoutsikos P, Miners JO.

Expert Opin Drug Metab Toxicol. 2005 Oct;1(3):399-408. Review.

PMID:
16863452
39.
40.

In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises.

Miners JO, Knights KM, Houston JB, Mackenzie PI.

Biochem Pharmacol. 2006 May 28;71(11):1531-9. Epub 2006 Feb 7. Review.

PMID:
16455060
41.
42.
43.

Polymer supported chromium porphyrin as catalyst for polycarbonate formation in supercritical carbon dioxide.

Stamp LM, Mang SA, Holmes AB, Knights KA, de Miguel YR, McConvey IF.

Chem Commun (Camb). 2001 Dec 7;(23):2502-3.

PMID:
12240035
44.
45.

Xenobiotic-CoA ligases: kinetic and molecular characterization.

Knights KM, Drogemuller CJ.

Curr Drug Metab. 2000 Jul;1(1):49-66. Review.

PMID:
11467080
47.

In vitro covalent binding of nafenopin-CoA to human liver proteins.

Sallustio BC, Nunthasomboon S, Drogemuller CJ, Knights KM.

Toxicol Appl Pharmacol. 2000 Mar 1;163(2):176-82.

PMID:
10698675
48.

Role of hepatic fatty acid:coenzyme A ligases in the metabolism of xenobiotic carboxylic acids.

Knights KM.

Clin Exp Pharmacol Physiol. 1998 Oct;25(10):776-82. Review.

PMID:
9784915
49.

Lack of effect of gender and oral contraceptive steroids on the pharmacokinetics of (R)-ibuprofen in humans.

Knights KM, McLean CF, Tonkin AL, Miners JO.

Br J Clin Pharmacol. 1995 Aug;40(2):153-6.

50.

Kinetic characteristics of rat liver peroxisomal nafenopin-CoA ligase.

Roberts BJ, MacLeod JK, Singh I, Knights KM.

Biochem Pharmacol. 1995 May 11;49(9):1335-9.

PMID:
7763316

Supplemental Content

Loading ...
Support Center